Physician profile
Eugene Shifrin
NPI 1649271164
$3,475.48
in general payments reported to CMS, 2019-2025
25 companies · $683 in 2025
The $683 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $312 · 2021: $842 · 2022: $286 · 2023: $552 · 2024: $333 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $493.62 | 2022-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol, Miebo |
| Alcon Vision LLC | $328.82 | 2020-2025 | Rocklatan, Tryptyr, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $321.04 | 2021-2024 | Lipiflow System Activator (Disposable) |
| Johnson & Johnson Vision Care, INC. | $279.98 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $255.33 | 2019-2025 | |
| Allergan, INC. | $230.09 | 2019-2022 | |
| Dompe US, INC. | $201.64 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $164.50 | 2023 | |
| Kala Pharmaceuticals, INC. | $146.29 | 2021-2022 | |
| Visioneering Technologies, INC. | $145.35 | 2019 | |
| Oyster Point Pharma, INC. | $141.58 | 2023-2024 | Tyrvaya |
| Abbvie INC. | $123.71 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.29 | 2020-2021 | |
| Ivantis, INC | $93.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $80.79 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $75.79 | 2023 | Myday Contact Lens |
| Thea Pharma INC. | $55.71 | 2024-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $48.16 | 2019-2020 | |
| Rxsight INC | $47.06 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Harrow Eye, LLC | $27.28 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $23.36 | 2020 | |
| Akorn Operating Company LLC | $22.88 | 2021 | |
| Shire North American Group INC | $21.13 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.89 | 2025 | Syfovre |
| Sight Sciences, INC. | $17.19 | 2023 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Shifrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.